biopharma

Market Access

Graphic of an upward trajectory arrow with woman and telescope atop

The biopharma outlook for 2025: Opportunities and challenges

With the Federal Reserve poised to implement interest rate cuts (albeit fewer than earlier forecasts assumed) and FTC leadership turnover anticipated, there may be broader shifts in how cap

R&D

Graphic of man with briefcase using large magnifying glass to search for something

Focusing too many R&D resources on one drug: The hidden cost...

Drug development is a high-stakes, high-cost endeavour.

R&D

Partner Content

EHS&S for Biopharma & Pharma Summit

Implementing Corporate & Regulatory-Guided EHS Practices to Achieve Zero Biosafety, Ergonomic & Chemical Incidents for Employee Safety Across Global Facilities

Sales & Marketing

Evolving HCP access requires a new connected approach to bui...

Specialty medicines – treatments designed for very small patient populations with complex and rare conditions – are on the rise.

Digital

How to deal with fragmented data - A $12.9 million challenge

In the age of AI, large data sets – like the treasure trove of customer data most biopharma companies are sitting on – are an invaluable asset.

R&D

Partner Content

LEAP HR: Emerging Biopharma

Lead The Future in Emerging Biopharma: Revolutionize Your HR Strategy, Develop Top Talent & Empower Your Team to Secure Success Amidst Industry Turbul